Close Menu

NIPS

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.

In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.

The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.

Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.

For the half year ended Sept. 30, Yourgene booked £8.2 million ($10.7 million) in revenues, up from £7.8 million during the same period last year.

Natera said that the expanded coverage by Centene will add 24 million people for whom the Panorama noninvasive prenatal test will be covered.

The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.

The company is selling 4,166,666 shares of its common stock at a price of $60 per share in the offering, which is expected to close Sept. 15.

The organization had previously only recommended the use of noninvasive prenatal testing in individuals 35 and older or with other known risk factors.

Pages